drugset / Trial / NCT01672775

A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

NCT01672775

Phase 1 Completed 34 enrolled Agensys, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and pharmacokinetics and assess the immunogenicity and effectiveness of AGS-16C3F in subjects with renal cell cancer (RCC).

Timeline

Start
2012-07-18
Primary completion
2017-02-21
Completion
2017-02-21

Drugs

EvaluationDrugModalityDoseRoute
Subject AGS-16C3F Unknown Intravenous